PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.10%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-6.32%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-22.67%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-22.67%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-31.20%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-33.33%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-37.50%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.13%
Slight or no buybacks while AVGO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
6.67%
Slight or no buyback while AVGO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-42.47%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-131.26%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
926.57%
10Y CAGR of 926.57% while AVGO is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
143.90%
5Y CAGR of 143.90% while AVGO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
79.87%
3Y CAGR of 79.87% while AVGO is zero. Bruce Berkowitz would see if small gains can accelerate to a more decisive lead.
2599.56%
OCF/share CAGR of 2599.56% while AVGO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
207.67%
OCF/share CAGR of 207.67% while AVGO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
47.63%
3Y OCF/share CAGR of 47.63% while AVGO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
1673.48%
10Y net income/share CAGR of 1673.48% while AVGO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
666.76%
Net income/share CAGR of 666.76% while AVGO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
149.80%
3Y net income/share CAGR of 149.80% while AVGO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
2155.17%
Equity/share CAGR of 2155.17% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
143.96%
Equity/share CAGR of 143.96% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
102.52%
Equity/share CAGR of 102.52% while AVGO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.20%
Firm’s AR is declining while AVGO shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
17.18%
Inventory growth of 17.18% while AVGO is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
1.60%
Asset growth of 1.60% while AVGO is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
4.42%
BV/share growth of 4.42% while AVGO is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
11.74%
We increase R&D while AVGO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
1.94%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.